Clinical trials in orthodontics often have as a primary outcome the total duration of fixed appliance treatment from placement to removal of the appliances. This is one of the most clinically relevant outcomes to the patient and orthodontist because prolonged treatment times are associated with adverse effects, such as patient burnout and the development of white spot lesions or root resorption. Data from existing randomised trials indicate that the outcome of treatment duration is normally distributed and that an average duration of 20 months with a Standard Deviation (SD) of about 5 months might be a realistic estimate to expectalthough large variability in treatment times does exist.
A group of orthodontic researchers plans to conduct a two-group parallel randomised clinical trial to assess the effect of corticotomy on the reduction of overall treatment duration. However, disheartened by the large sample size yielded from a formal statistical sample size calculation, they arbitrarily decide to recruit a total of 20 patients in the two treatment groups and describe the study as a 'pilot'. Their justification is that as this is a randomised trial the possibility of bias will be low and their results will still be robust, despite the objectively small sample size.
After completing their trial and collecting data, they routinely check for normal distribution of their outcome treatment duration with the Shapiro-Wilk test; however, this gives them a p value of .01 which indicates an absence of normality. Therefore, they adjust their descriptive and inferential statistics to those appropriate for non-normal distributions. Finally, they conclude that although this is a pilot study with a small sample, the randomised nature means that the results are robust and at low risk of bias.
Which of the following statements are correct, if any:
(a) Having a small sample in a trial cannot affect the average treatment duration actually measured in the trial;
(b) Having a small sample in a trial might affect the precision of the estimated results; (c) Having a small sample in a trial cannot affect the 'normality' (or lack thereof) of the trial's outcome; and (d) Randomisation can safeguard against any limitations associated with a small sample size.
Discussion
To illustrate the first statement, we generate a large parent sample of 200 patients that should correspond to the 'true' mean duration of 20 months and SD of 5 months. As all samples are subject to a certain variability, we end up with the sample of 200 patients having a mean of 19.4 months and SD of 5.4 months, which is pretty close to what we initially aimed. If we now draw random trial samples of 20 patients each from the parent sample, we see an interesting finding (Figure 1 ). Although many of the drawn samples (blue boxes) are relatively close to the 'true' average duration of 20 months (green box), the mean values in the trials vary considerably, such as sample H with a mean duration of 18.2 months. This is exaggerated even more if we further reduce the recruited sample size from 20 to 10 patients, where the mean values of the small trials (red boxes) are generally further away from the true mean (green box). We see therefore signs of bias of the estimator, in which the sample size of a trial together with pure chance can influence the results that are actually measured in a trial. Therefore, statement A is false. Furthermore, we can assess the precision of the measured results in the drawn samples by calculating the 95% Confidence Intervals (CIs) of the mean treatment duration in each trial. We would then see that the parent sample A has a very narrow 95% CI spanning only about 1.5 months (19.2 to 20.7 months), which indicates high precision (Figure 1) . However, trials with 20 patients (coloured blue) have much wider 95% CIs of at least 4 months. This is again further exaggerated in trials with 10 patients (coloured red), where the 95% CIs span almost 10 months! We see, therefore, that even in a perfectly random setting, the sample size of a trial is closely related to precision. Therefore statement B is correct.
In order to assess the truth of statement C, one method would be to plot the distributional histograms of the drawn trial samples and perform the ShapiroWilk test to formally assess the normal distribution of treatment duration. As Figure 2 indicates, the distribution of the parent sample A resembles that of a normal distribution (top) and this is confirmed by a non-significant Shapiro-Wilk test (p > .05). However, great variability in the outcome distribution can be seen among both trials with 20 patients (middle row) and with 10 patients (bottom row). Also, formal testing for normality with the Shapiro-Wilk test gives diverse results and indicates that some trials from the middle or bottom row have non-normally distributed outcome (p < .05). This would lead the authors of the trial to conclude that treatment duration is not normally distributed and choose a different statistical analysis plan that better fits non-normally distributed data. Therefore, statement C is wrong.
Finally, randomisation in a trial is employed to ensure baseline equivalence of the randomised groups for all known or unknown factors that could potentially affect treatment duration. This means that any difference in the final treatment duration of the randomised groups can be most confidently attributed to their different treatment protocol. Randomisation cannot safeguard from the limitations of having a small sample, which can ultimately affect the results of the trial and their validity--a phenomenon that is termed 'small study effects' (Dechartres et al. 2013) . This is the reason why the CONSORT (Consolidated Standards of Reporting Trials) statement (Moher et al. 2010 ) has distinct items for describing sample size calculation and randomisation, as these are two separate procedures independent of each other.
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